BDR Receives DCGI Approval for the Launch of Favipiravir to Treat COVID-19 in India

Mumbai : BDR Pharmaceuticals today announced the launch of Favipiravir for the treatment of COVID-19 patients in India.

BDR Pharma has received an approval from Drugs Controller General of India (DCGI) to manufacture Favipiravir to treat mild to moderate patient with Covid-19 symptoms under the brand name BDFAVI. This approval comes after being one of the first companies to develop Remdesivir in the country and supply it on compassionate grounds to those suffering from the virus.


“BDR has been at the forefront in benefiting patients in this pandemic and supporting India’s fight against COVID-19. This launch further strengthens our commitment to the patients to provide better outcomes for patients with mild to moderate COVID symptoms in India” said Mr.Dharmesh Shah, CMD, BDR Pharma. “Currently, with over 18lac cases in India, we believe this approval comes at a time when cases are at an all-time high in the country. We aim to meet the demand of every patient while maintaining the highest quality during these critical times through improved medical solutions.”

BDR Pharma has persistently been at the forefront in supporting India’s fight against COVID-19. In the short span of 4 months the company has launched 2 path- breaking drugs, to meet the increasing patients’ needs and provide timely therapy option during the pandemic.Favipiravir, an antiviral drug used for the treatment of influenza in Japan since 2014, was approved by Drug Controller General of India for the treatment of mild to moderate cases of COVID-19 in India.

Favipiravir confirmed encouraging clinical evidence, with positive results in mild to moderate Covid-19 cases. BDR pharma has developed Favipiravir tablets in 200mg strengths with a strip of 10 tablets with the highest safety and manufacturing protocols in place to meet national and international demands.

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.


Related Articles

Leave a Reply

Back to top button